Palatin Technologies Inc. (NYSEAMERICAN: PTN) has confirmed that it will release its earnings on Monday, September 27, 2021.
What to look for
The company has progressed using its novel melanocortin agonist in treating patients with autoimmune and inflammatory conditions. When the company released its Q3 2021 results, CEO Carl Spana said that it was to commence Phase 3 study of PL9643 in 2H 2021 for dry eye disease patients. PL9643 is an emerging profile with a rapid therapeutic onset and good tolerability profile with a distinct advantage over the available therapies. In addition, the company is making press with the Vyleesi program, and in the past quarter, there were considerable increases in prescriptions, gross sales, net sales, and insurance coverage. The exceptional Vyleesi sales are expected to reflect in Q4 results when the company releases its earnings.
Earnings: Stockearning’s Estimated EPS for Q4 2021 is expected to improve from the loss of $0.02 reported in Q3. Net loss in Q3 2021 was $5.7 million or $0.02 per share versus a net loss of $5.4 million or $0.02 per share a year ago. In the past quarter, the company topped estimates of a net loss of $0.04 per share with EPS of $0.02. Historical performance shows that in the past 12 quarters, the company has topped estimates four times (33%) and missed thrice (25%).
Revenue: In the third quarter, the company reported net product revenue of $88,741, consisting of the net revenues of Vyleesi. Vyleesi's gross sales were $1.78 million compared to the prior quarter, when gross sales were $943,950. Gross product sales were up 89%, prescriptions increased 24%, and net revenue was up 154%. The company ended the quarter with cash and equivalents of around $68.6 million and accounts receivables of $1.9 million.
Stock movement: Since the last earnings release, the stock has lost 5.9% to the previous close of $0.48 a share. Palatin Technologies' share price has been DOWN 17 times in the past 24 quarters following the earnings release. So, the historical price reaction suggests a 70% chance for the share price to go DOWN after the earnings release on Monday. According to the Stockearning algorithm, the predicted first-day move after earnings release is 5%, while the predicted seventh-day move is 9%.
Related News:
Fonar Corporation (NASDAQ: FONR) Earnings Expectations, 52% chance For Stock Price To Fall.
Concentrix Corporation (NASDAQ: CNXC) Expects Revenue of Between $1.35B and $1.4B In Q3 2021.